title: Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
abstract: Patients with metastatic colorectal cancer (mCRC) frequently experience treatment-related adverse events (AEs), which may lead to nonadherence or discontinuation from their treatment regimen. In the phase 3 CORRECT study, the addition of regorafenib to best supportive care (BSC) significantly increased overall survival and progression-free survival compared with placebo plus BSC in patients with mCRC who had progressed on all approved standard care therapies. Although regorafenib showed an acceptable safety profile, patients experienced treatment-related AEs such as hand-foot skin reaction, hypertension, oral mucositis, diarrhea, fatigue, and liver abnormalities. The goal of this article is to help oncology nurses implement a strategic, proactive approach to AE management in patients mCRC treated with regorafenib. The article reviews the most common AEs associated with regorafenib in patients who participated in the CORRECT study and provides a strategy and practical measures that nurses can apply to AE management. In addition, the article provides direction and guidance for educating patients and their caregivers on recognizing and managing potential side effects of regorafenib.
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Jessica
authors.initials: J
authors.lastname: Mitchell
authors.affiliation: University of Southern California Norris Comprehensive Cancer Center in Los Angeles.
authors.forename: Taline
authors.initials: T
authors.lastname: Khoukaz
authors.affiliation: Charleston Hematology Oncology Associates in South Carolina.
authors.forename: Deborah
authors.initials: D
authors.lastname: McNeal
authors.affiliation: Jackson Oncology Associates in Mississippi.
authors.forename: Lori
authors.initials: L
authors.lastname: Brent
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D009362:Neoplasm Metastasis; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D013280:Stomatitis / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib
keywords: biotherapy/targeted therapy; gastrointestinal malignancies